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Equivalent efficacies of meropenem and ceftazidime as empirical 
monotherapy of febrile neutropenic patients
The Meropenem Study Group of Leuven, London and Nijmegen*
The efficacies of meropenem, a novel carbapenem, and ceftazidime, as empirical 
therapy of febrile neutropenic patients, were compared in a prospective, randomized 
clinical trial. One hundred and twelve adult patients were given meropenem 1 g tds iv 
for 153 episodes of fever, while 109 patients received ceftazidime 2 g tds iv for 151 
episodes. All patients survived the first 3 days of therapy and, by the end of the 
treatment courses, 67 (44%) episodes had responded to meropenem, compared with
62 (41 %) to ceftazidime. Eighty (53%) episodes initially treated with ceftazidime and
63 (41%) episodes treated with meropenem were considered to have failed treatment 
because it was thought necessary to administer additional antibacterial agents; 
however, modifications were made twice as often because of fever that persisted beyond 
2-3 days than because of obvious causes of failure such as persistent infection. Three 
patients in the ceftazidime group and five in the meropenem group died. Meropenem 
was well tolerated, with no reports of nausea or toxicity to the central nervous 
system. Although ceftazidime was shown in the present study to be as effective as 
meropenem, the broader spectrum of activity of meropenem against Gram-positive 
cocci suggests that it might be more appropriate as empirical therapy of febrile 
neutropenic patients who are at high risk of acquiring infections caused by these 
bacteria.
Introduction
Ceftazidime has been used as monotherapy for febrile neutropenic patients for 
more than a decade (De Pauw et al., 1985; Pizzo et al., 1986; Sanders, Powe & 
Moore, 1991) and has been shown to be as effective as standard regimens (De Pauw 
et a l 1994). However, the addition of other antibiotics is frequently necessary in 
order to provide optimal cover for coagulase-negative staphylococci, which are 
usually associated with central venous catheters (Raad & Bodey, 1992), and viridans 
streptococci which gain access to the bloodstream as the result of mucositis caused 
by intensive chemotherapy and which are occasionally associated with shock and 
the adult respiratory distress syndrome (ARDS) (Cohen et al., 1983; Villablanca et al,, 
1990).
Carbapenems exhibit in-vitro activities against aerobic Gram-negative bacilli (AGNB) 
which are similar to those of the cephalosporins, but have greater activities against
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Gram-positive bacteria (Edwards et a l , 1989). These agents might therefore be superior 
to cephalosporins as initial therapy of febrile neutropenic patients, owing to the marked 
increase in the incidence of infections caused by Gram-positive organisms that has 
resulted from recent changes in clinical practice (EORTC International Antimicrobial 
Therapy Cooperative Group, 1990). However, the administration of imipenem/cilastatin, 
the first carbapenem to become available for clinical use, is frequently associated with 
nausea and vomiting in neutropenic patients (Winston et a l, 1991; Leyland et a l, 1992) 
and can induce seizures (Bodey et al., 1987). Meropenem, a novel carbapenem, might be 
a more acceptable alternative since it retains the broad spectrum of activity of imipenem 
(Donnelly et a l, 1992a) but does not cause nausea and vomiting and is apparently free 
of central nervous system toxicity (Donnelly et a l , 1992ft). The aim of this unblinded, 
prospective, multicentre trial was to compare the efficacy and tolerability of meropenem 
with that of ceftazidime as empirical therapy of febrile episodes in neutropenic adult
patients.
Patients and methods
Patients
Adult patients receiving intensive chemotherapy for haematological malignancies 
whose neutrophil counts had fallen, or were expected to fall within the next 48 h, 
to <0-5 x 109/L and who were considered febrile, having developed axillary tempera­
tures of >38*5°C, were eligible for inclusion into the trial. Patients were excluded for 
one or more of the following reasons; allergy to penicillins or cephalosporins; a 
serum creatinine concentration of > 265 pmol/L; or the previous administration of 
parenteral antibiotic therapy during the same neutropenic episode. The study was 
approved by the Ethics Committee in each participating centre and consent was obtained 
from all patients.
Treatment
Patients were randomized to receive brief intravenous infusions of either ceftazidime 
(2 g tds) or meropenem (1 g tds). Allocation to one or the other regimen was achieved by 
an investigator opening the next in a sequence of sealed envelopes containing numbers 
generated by a computer in each centre. Treatment was initiated immediately after 
completion of a comprehensive physical examination and after samples of blood and 
other appropriate specimens (determined according to clinical signs) had been obtained 
for culture. The use of prophylactic antibacterial agents was prohibited for the duration 
of the trial.
Therapy was continued until a patient was free of all signs and symptoms of infection 
for at least 2 days when the neutrophil count exceeded 05 x 109/L or for 5 consecutive 
days when the count remained below 0-5 x 109/L. Ceftazidime or meropenem was 
substituted with an alternative agent if a patient experienced a severe adverse 
event. One or more additional antimicrobials were given for the following reasons: if a 
pathogen which was resistant to the empirical regimen was isolated; if a patient was not 
responding to treatment, as demonstrated by a marked deterioration in the clinical 
condition, persistent bacteraemia or pyrexia persisting for > 72 h; if there was recurrence
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of fever; or if, following resolution of the original infection, a patient developed another 
clinically or microbiologically defined infection.
Investigations
Patients were examined daily, routine haematological investigations were carried out 
daily or on alternate days and routine liver and renal function tests were performed at least 
once weekly. Additional blood cultures were obtained on the second or third day of 
treatment and whenever there was recurrence of fever. Chest X-rays and invasive 
diagnostic procedures such as bronchoalveolar lavage were performed when indicated.
Bacteriological isolates were identified according to standard techniques and antibiotic 
susceptibilities were determined by the disc diffusion method; an organism was considered 
resistant to ceftazidime if the inhibitory zone diameter was <14 mm (National 
Committee for Clinical Laboratory Standards, 1990) and to meropenem when the 
diameter was <10 mm (Zeneca Pharmaceuticals, data on file).
Classification of infection
Bacteraemia was defined as the isolation of a recognized pathogen from at least one set 
of blood cultures or of the same strain of a coagulase-negative staphylococcus or a 
Corynebacterium sp. from at least two sets of blood cultures obtained by separate 
venepunctures. A putative site of infection was classified as a clinically defined infection 
unless confirmed by the isolation of a recognized pathogen, either from the site itself or 
from blood cultures, in which case it was classified as a microbiologically defined 
infection. All other episodes were regarded as fevers of unknown origin. Death was 
attributed to infection only when it occurred as a direct consequence and a 
microbiologically defined infection that developed during an initial course of treatment 
was classified as a superinfection.
Assessment of response to therapy
Each treatment episode was assessed according to guidelines proposed by the 
Immunocompromised Host Society (Immunocompromised Host Society Consensus 
Panel, 1990). Briefly, therapy was regarded as having been successful if all signs and 
symptoms of infection resolved without modification of the initial empirical regimen. If 
it was necessary for an antifungal or antiviral agent to be added to the initial regimen, 
the episode was considered to have been a response to a modified regimen, whereas 
the addition of one or more other antibacterial agents or death directly attributable 
to infection constituted failure. If treatment was discontinued for reasons unrelated to 
infection, such as allergy or sudden death due to haemorrhage, the episode was considered 
unevaluable for efficacy. All patients were included in the assessment of safety and 
tolerance.
The bacteriological responses of microbiologically defined infectious episodes to the 
study regimens were assessed only if follow-up cultures had been obtained before 
the initial treatment was either modified or discontinued. The original pathogen was 
considered to have been eradicated if it was not isolated from a follow-up culture, while 
recovery of this organism from a follow-up culture was classified as persistence.
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Statistical analysis
Success rates were expressed as odds ratios, where unity indicated equivalence, a value 
> 1 suggested superiority of meropenem and a value < 1 denoted the superiority of 
ceftazidime. Lack of statistical significance was inferred when the 95% confidence 
intervals (Cl) for the odds ratios encompassed unity, although formal analysis was 
also undertaken with the Chi-square test without a correction factor.
Results
Patients
A total of 338 febrile episodes in 248 neutropenic patients were treated with either 
ceftazidime (168 episodes) or meropenem (170 episodes). Thirty-four episodes were 
subsequently excluded from the analysis of efficacy for the following reasons: failure 
to fulfil the entry criteria (12 episodes and 15 episodes treated with ceftazidime and 
meropenem respectively); fever shown not to be caused by a bacterial pathogen (four 
episodes treated with ceftazidime and two with meropenem); and non-evaluability (one 
patient in the ceftazidime group who died of haemorrhage on the ninth treatment day 
after all signs and symptoms of infection had resolved). Therefore, 151 and 153 episodes 
treated with ceftazidime and meropenem respectively were available for analysis, 
The patients in the two groups were comparable with respect to age, sex, underlying 
disease, degree of neutropenia and the use and type of oral prophylaxis and central venous 
lines (Table I).
Details of febrile episodes
The two groups were similar in terms of the classification of febrile episodes (Table II). 
Microbiologically and clinically defined infections together accounted for 70% of
Table I. Demographic features of the patient populations
Characteristic
Treatment group 
ceftazidime meropenem
Number of patients 109 112
Mean age (range) (years) 42(14-78) 42 ( 15-74)
Number (%) of males 73 (67) 61 (54)
Number (%) with acute leukaemia 79 (72) 79 (71)
Number (%) with central venous lines 105 (70) 115(75)
Number (%) receiving prophylaxis with
fluoroquinolones 83 (55) 77 (50)
other agents 24 (16) 28(18)
Number (%) of episodes" with neutrophil counts (x 109/L) at
entry of
< 0*1 102 (76) 106 (78)
0'M)-5 29 (22) 25(19)
>0*5 3(2) 4(3)
Number of assessable episodes 151 153
flNo data available for 17 episodes in the ceftazidime group and IB in the 
meropenem group.
Meropenem monotherapy of febrile neutropenic patients 189
Table ü . Categories of febrile episode
Category
Number (%) of episodes 
ceftazidime meropenem
Microbiologically defined infection 81 (54) 82 (54)
bacteraemia only 52 48
bacteraemia with localized infection 27 31
localized infection without bacteraemia 2 3
Clinically defined infection 24(16) 28(18)
Fever of unknown origin 46(30) 43(28)
episodes in the ceftazidime group and 72% of those in the meropenem group; 79 (52%) 
episodes in each group were associated with bacteraemia. Gram-positive bacteria 
(alone or with other organisms) caused 63 (80%) of the bacteraemic episodes treated with 
ceftazidime and 68 (86%) of those treated with meropenem (Table III). Susceptibility to 
ceftazidime was determined for 72 of the 103 organisms isolated from blood cultures 
obtained from patients treated with this agent; 22 (31%) of these isolates, including 14 
strains of coagulase-negative staphylococci, two of Corynebacterium jeikeium, one each 
of Streptococcus sanguis, Enter ococcusfaecalis s a Corynebacterium sp., an Achromobacter 
sp, and a Flavobacterium sp. and the Micrococcus spp., were resistant. Similarly, 72 of 
the 97 organisms isolated from the blood cultures of patients treated with meropenem 
were tested against this carbapenem and 15 (19%), including ten strains of 
coagulase-negative staphylococci and one each of Stomatococcus mucilaginosus, a 
viridans streptococcus, Stenotrophomonas maltophilia, Aerococcus viridans and 
E. faecalis, were resistant.
Specimens were obtained in respect of only 25 of 51 (49%) episodes of localized 
infection treated with ceftazidime and from only 27 of 59 (46%) of those treated with 
meropenem; a pathogen was isolated in only six and eight of these episodes respectively. 
Five of the ceftazidime-treated episodes were catheter exit site infections, caused by 
coagulase-negative staphylococci (together with a strain of C. jeikeium in one patient) 
(four cases) and Staphylococcus aureus (one case); two of the coagulase-negative 
staphylococci were resistant to ceftazidime. The sixth episode in the ceftazidime group 
was an infection of the oral mucosa caused by herpes simplex. Five of the episodes treated 
with meropenem were also catheter exit site infections, caused by strains 
of coagulase-negative staphylococci (three cases), Enterobacter cloacae (one) and both 
S. aureus and S. maltophilia (one). The other localized infections in the meropenem 
group included one case each of a urinary tract infection caused by Escherichia 
coli, necrotising pharyngitis caused by Pseudomonas aeruginosa and a lower respiratory 
tract infection in a patient from whose sputum Aspergillus terreus was isolated. One 
strain of Staphylococcus epidermidis and the S. maltophilia strain were resistant to 
meropenem.
Clinical response rates
Ceftazidime was administered for a mean of 11 *3 days and meropenem for a mean of 10-7 
days. The rates of defervescence were also similar for the two groups (Figure 1); it was 
noteworthy that approximately 75% of patients were still febrile after 3 days of therapy.
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Successful response. Of the 151 evaluable episodes treated with ceftazidime and the 153 
treated with meropenem, 62 (41%) and 67 (44%) respectively responded to the initial 
re g im e n s  without modifications (odds ratio, 1.1; 95% Cl, 0*71—1 -76) (Table IV). A higher 
percentage of the bacteraemic episodes without localized infection which were treated 
with meropenem were classified as successes, compared with those treated with
Table IIL Causes of bacteraemic episodes
Bacterium
Number of isolates 
ceftazidime meropenem
Gram-positive 57 65
viridans streptococci 23a,b 24c
coaguiase-negative staphylococci 18M 2Ad
Corynebacterium spp. 4a 3
S. mucilaginosus 3a,e 3
E, faecalis 3a 1
Streptococcus spp. 3f 4a
S. aureus \8 1
Micrococcus spp. 1 1
Actinomyces sp. 1
Propionibacterium spp. 2°
A. viridans 1
Bacillus sp. 1
Aerobic Gram-negative bacilli 19 14
E. coli 8* 4
Klebsiella spp. 2" 3a
Citrobacter freundii 1
E. cloacae 4
Serratia marcescens 1'
P. aeruginosa 2 2a
Pseudomonas fluorés cens V
Pseudomonas paucimobilis \k
S. maltophilia 1 V
Achromobacter sp. 1
Flavobacterium sp, 1
Anaerobes 3 0
Bacteroides fragil is 2'
Fusobacterium sp. 1*
Total 79 79
"One episode also caused by a coaguiase-negative staphylococcus, 
fiOne episode caused by two different strains.
"Ten episodes also caused by coaguiase-negative staphylococci and one by a 
Micrococcus sp.
‘'One episode caused by three different strains. 
eOne episode also caused by a viridans streptococcus.
T^wo episodes also caused by coaguiase-negative staphylococci.
*AIso caused by a Corynebacterium sp.
ABoth episodes also caused by E. coli.
'Also caused by a viridans streptococcus and a coaguiase-negative staphylococcus. 
'Also caused by a coaguiase-negative staphylococcus.
*Also caused by E. coli> a Corynebacterium sp. and a coaguiase-negative 
staphylococcus.
'One episode also caused by an Eubacterium sp. and a coaguiase-negative 
staphylococcus.
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Days of treatment 
Figure 1. Rates of defervescence: —, meropenem; — , ceftazidime.
ceftazidime (47% vs 31 %), but the difference was not statistically significant. The response 
rates for the other categories of febrile episode were similar for both groups.
Response to a modified regimen. Antifungal agents were administered as first 
modifications of the empirical regimens in four episodes treated with ceftazidime and in 
ten treated with meropenem. Similarly, acyclovir was prescribed for two and eight 
episodes in the ceftazidime and meropenem groups respectively. A further modification 
of therapy was required for three of the six episodes initially treated with ceftazidime (two 
episodes treated with vancomycin and one with amphotericin B (AMB)) and for three 
of the ten episodes initially treated with meropenem (two episodes treated with AMB and 
one with penicillin).
Failure of therapy. Overall, 83 (55%) of ceftazidime-treated episodes and 68 (44%) of 
meropenem-treated episodes were classified as treatment failures.
Treatment was considered to have failed because at least one other antibacterial agent 
was added to the initial regimen in 80 (53%) of episodes treated with ceftazidime and in
63 (41%) of episodes treated with meropenem (P < 0*001) (Table IV). Treatment was 
modified for both clinically defined and bacteraemic episodes (without localized 
infections) approximately twice as often in the ceftazidime group as in the meropenem 
group, but there were no significant differences between the groups in terms of the 
frequencies of modification for the other categories of febrile episode. The reasons for 
the first modification were similar in each group (Table V). Persistent pyrexia was 
the principal reason, accounting for 71 % and 79% of first modifications in the ceftazidime 
and meropenem groups respectively, although fever had persisted for <72h in 
approximately 60% of cases. Persistent bacteraemia and resistance of a pathogen to the 
empirical regimen together led to modifications in 17% of episodes treated with 
ceftazidime and in 8% treated with meropenem; strains of S. epidermidis accounted for 
seven of the 13 pathogens in the former group and for three of the five in the latter group, 
Therapy was changed because of recurrence of either fever or infection in 13% of episodes 
in both groups. The most frequently prescribed antibiotics were the glycopeptides which 
comprised approximately 60% of first modifications in each group (Table VI). Treatment 
with these agents was initiated a mean of 5-1 days after starting therapy with ceftazidime 
and a mean of 4-8 days after starting therapy with meropenem. Although penicillin was 
administered more often for episodes initially treated with ceftazidime than for those
h i
Table IV. Response to therapy
Number (%) of episodes 
ceftazidime meropenem
Category of 
febrile episode success
response 
to a 
modified 
regimen
failure due 
to addition 
of other
antibacterials
failure 
due to
death total success
response 
to a 
modified
regimen
failure due 
to addition 
of other 
antibacterials
failure 
due to 
death tota
MicrobiologicaUy defined infection
bacteraemia only 16(31) 3(6) 33 (63) 52 23 (48) 10 (21) 13 (27) 2(4) 48
bacteraemia with localized
infection 4(15) 1(4) 19 (70) 3(11) 27 3(10) 1(3) 25 (81) 2 (6) 31
localized infection without
bacteraemia 2 (100) 2 3 (100) 3
Clinically defined infection 10 (42) 1(4) 13 (54) 24 13 (46) 4(14) 10(36) 1(4) 28
Fever of unknown origin 32 (70) 1 (2) 13 (28) 46 28 (65) 3(7) 12 (28) 43
Total 62 (41) 6(4) 80 (53) 3(2) 151 67 (44) 18 (12) 63 (41) 5(3) 153
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Table V. Reasons for modifying empirical regimens by adding one or more
antibacterial agents
Number (%) of episodes
Reasons for modification ceftazidime meropenem
Persistent fever 57(71) 50 (79)
Resistant pathogen 7(9) 2(3)
Persistent infection 6 (8) 3(5)
Recurrence of fever or new infection 10(13) 8(13)
Total 80 63
treated with meropenem, the other second-line antibiotics were given equally frequently 
in both treatment groups. Two or more additional agents were prescribed concurrently 
in 13 and ten episodes treated with ceftazidime and meropenem respectively. Further 
modifications were required for 47 (59%) of episodes where ceftazidime was administered 
initially and for 32 (51%) of those where meropenem was given.
Failure of therapy was attributed to death from infection in three (2%) patients treated 
with ceftazidime and in five (3 %) given meropenem. Two of the patients in the ceftazidime 
group had bacteraemias caused by susceptible strains of P. aeruginosa. One of these died 
of pneumonia on the fourth day of treatment, despite eradication of the pathogen from 
the bloodstream, and the other of multi-organ failure on the fifth day of treatment, 1 day 
after tobramycin had been added to the regimen; no further specimens were obtained for 
culture from the latter patient. The third patient developed ARDS and died 8 days after 
beginning therapy with ceftazidime, Strains of E.faecalis and S. epidermidis were isolated 
from this patient’s blood cultures, but their susceptibilities were not recorded and the 
organisms persisted until penicillin and vancomycin had been administered. Three 
patients died of pneumonia 8, 9 and 20 days respectively after beginning therapy with 
meropenem. Although blood cultures from the first of these patients were sterile, he was 
still given vancomycin and erythromycin. The second patient had a bacteraemia caused 
by a strain of S. epidermidis which was eradicated before a glycopeptide was given, despite 
being resistant to meropenem; this patient had also received AMB. Strains of S. 
epidermidis and Streptococcus mitis were recovered from the blood cultures of a third
Table VI. Antibacterial agents added as modifications of
empirical regimens
Number (%) of prescriptions 
Antimicrobial ceftazidime meropenem
Glycopeptide 51 (61) 40 (59)
/?-lactam 17 (20) 12(17)
Aminoglycoside 9(11) 8 (12)
Other agents 7(8) 8 (12)
Total 84" (100) 68 (100)
“The total number o f agents exceeds the num ber o f  episodes 
as more than one agent was given as first m odification in 13 and 
ten episodes treated initially with ceftazidime and meropenem 
respectively.
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Figure 2. Kaplan-Meier plot showing the times patients received initial monotherapy: —, meropenem; — ,
ceftazidime.
patient. Both isolates were susceptible to meropenem and were eradicated before 
treatment with vancomycin was initiated. This patient had also been given fluconazole 
and ÀMB for a suspected fungal infection, A fourth patient died of ARDS after 23 days 
of treatment with meropenem for bacteraemia caused by strains of 5. mitis and S. 
epidermidis. The antimicrobial susceptibilities of these organisms were not determined, 
but both were eradicated before penicillin and teicoplanin were added to the regimen. This 
patient was subsequently given AMB, acyclovir and erythromycin. The fifth patient died 
of peritonitis following bowel perforation 17 days after beginning treatment for 
bacteraemia caused by a susceptible strain of S. epidermidis which was eradicated before 
teicoplanin was administered; this patient also received metronidazole and gentamicin.
Modifications of therapy
Overall, therapy was modified with equal frequencies in the two groups (Figure 2); the 
percentages of patients receiving either meropenem or ceftazidime alone declined at 
a similar rate. Modifications were made by the third day in 14 (9%) episodes treated with 
ceftazidime and in 12 (8%) treated with meropenem; in all but two episodes in each group, 
the newly-administered drugs were antibacterials. By the end of the treatment courses, 
each of the individual agents had been prescribed with the same frequencies in the two
Table VII. All modifications of initial empirical therapy
Number of prescriptions 
(as a percentage of all assessable episodes) 
Antimicrobial ceftazidime meropenem
Glycopeptide 65 (43) 53 (35)
P -lactam 29 (19) 19(12)
Aminoglycoside 19(13) 13(9)
Other antibacterials 24 (16) 20(13)
Antifungal 29 (19) 25(16)
Antiviral 1 2 (8) 10(7)
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treatment groups (Table VII), the glycopeptides having been administered approximately 
twice as often as the next most frequently prescribed group of drugs.
Bacteriological response rates
Overall, 81% and 71% of bacteraemic episodes were caused by isolates that were 
susceptible to meropenem and ceftazidime respectively. Fewer pathogens were eradicated 
by ceftazidime than by meropenem (P < 0-05) (Table VIII). While all AGNB were 
eradicated by meropenem, the Achromobacter sp., Flavobacterium sp. and Serratia 
marcescens strains were eradicated from patients receiving ceftazidime only after the 
administration of other agents. Superinfections developed in 14 patients treated with 
ceftazidime and in 17 given meropenem.
Adverse events
Rashes were reported during or after six (4%) episodes treated with ceftazidime, 
compared with only two (1%) treated with meropenem. Transient elevations of liver 
transaminase concentrations were detected in one and three patients in the ceftazidime 
and meropenem groups respectively. Six patients with previous histories of seizures and 
one with a focal central nervous system disease were treated with meropenem without 
experiencing adverse effects.
Discussion
The rapid initiation of broad spectrum antibacterial therapy has had a profound impact 
on the incidence of mortality attributable to infection in the febrile, neutropenic patient 
(Schimpff et al., 1971). While this practice has been adopted almost universally, it was 
initially assumed that only combination therapy was suitable for high-risk patients, such 
as those with acute leukaemia whose treatment induced severe and prolonged neutropenia 
(Hughes et a l., 1990), More recently, however, there has been a number of studies which 
have shown that monotherapy is equally effective (Pizzo et aL, 1986; Winston et al., 1991; 
Leyland et al., 1992; De Pauw et a l 1994) and is associated with a lower incidence of 
toxicity. These results generated considerable controversy, those opposing monotherapy 
being hesitant to accept it as an alternative to more standard regimens, principally because 
the early studies lacked statistical power (Hughes et ah, 1990). A similar criticism might 
also be applied to the present study which involved 311 febrile episodes but, since all 
patients survived the first 3 days of treatment (the true empirical period) and 75% of them 
were profoundly neutropenic, the results suggest that empirical therapy with a single agent 
at the very least prevents early death due to infection. Moreover, the majority of patients 
had received intensive chemotherapy for acute leukaemia, and yet, 96% survived 297 
febrile neutropenic episodes, survival rates which compare favourably with those reported 
for combination therapy (Pizzo et al., 1986; EORTC International Antimicrobial 
Therapy Cooperative Group, 1987; De Pauw et al., 1994).
The regimens evaluated in this study were shown to be equally effective; even the rates 
of defervescence were similar. Consistent with current trends, the ratio of Gram-positive 
to Gram-negative bacterial pathogens was almost 4:1. The predominance of 
coagulase-negative staphylococci as blood culture isolates reflects the extensive use of 
central venous lines in this patient population and is the most likely explanation for the
VO
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Table VUI. Relationship between antimicrobial susceptibility in vitro and eradication of bacteria on completion of monotherapy for bacteraemic
episodes
Ceftazidime Meropenem
no. of strains no. of strains no. of strains no. of strains
eradicated / eradicated/ eradicated/ eradicated/
Bacterium no. susceptible no. resistant no. susceptible no, resistant
Monomicrobial bacteraemia
viridans streptococci 9/11 8/9 1/1
coagulase-negative staphylococci 3/9 2/5 3/4
other Gram-positive bacteria 1/3 2/2 2/4 2/3
aerobic Gram-negative bacilli 5/6 0/2 6/6
Polymicrobial bacteraemia
coagulase-negative staphylococci 2/3 0/2 5/6 0/2
other Gram-positive bacteria 1/1 1/1
aerobic Gram-negative bacilli 2/3 1/2
Total 19/26 (73%) 6/16 (38%) 24/31 (77%) 7/12(58%)
Total no. of episodes caused by Gram-positive bacteria 12/17(71%) 6/14 (43%) 18/25 (72%) 6/10 (60%)
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widespread use of glycopeptides as second-line treatment since ceftazidime is perceived 
as having poor activity against Gram-positive bacteria. Meropenem, on the other hand, 
is more active in vitro against these organisms, and was therefore expected to be more 
effective as treatment for infections caused by them. Surprisingly then, there was little 
difference between the two groups in terms of the use of vancomycin and teicoplanin. 
Moreover, a third of patient episodes treated with meropenem were also treated with a 
glycopeptide, probably because of the tendency to supplement empirical regimens when 
fever persists, irrespective of the microbiological findings. Indeed, in this study, persistent 
fever was the most common reason for administering a glycopeptide, although 
Gram-positive bacteria persisted in only 17 of the 177 episodes in which such a drug was 
given. While the percentage of isolates resistant to ceftazidime was greater than that 
resistant to meropenem, as many as two-thirds of the strains were susceptible to this agent, 
confirming that modifications were usually made on clinical rather than microbiological 
grounds. There also seemed to be a tendency to prescribe a glycopeptide as a first 
modification because the risks of infection caused by Gram-positive bacteria were 
perceived as being high. Giving vancomycin or teicoplanin as second-line treatment for 
a fever lasting less than 4 days might therefore have obscured a genuine difference between 
the treatment groups, since the average duration of fever in neutropenic patients who have 
responded to initial therapy has been reported to be between 4 and 5 days (Novakova, 
Donnelly & De Pauw, 1991). There are compelling reasons, therefore, to restrict the 
glycopeptides to the treatment of patients with persistent infections, instead of 
administering them empirically, unless the anticipated incidences of morbidity and 
mortality attributable to infections caused by these organisms are exceptionally high 
(Donnelly et a l 1993). One could argue that combining meropenem with another agent 
with activity against Gram-positive bacteria is superfluous, except, perhaps, where 
methicillin-resistant strains of staphylococci are implicated. In support of this view, the 
administration of a glycopeptide in the present study was regarded as necessary in only 
50% of the febrile episodes caused by coagulase-negative staphylococci which were 
initially treated with meropenem, compared with almost all of those initially treated with 
ceftazidime.
Overall, only a minority of changes of therapy were made on objectively verifiable 
grounds, such as clinical deterioration, persistent bacteraemia, relapse or a new infectious 
episode. Rather, treatment was altered with equal frequencies in both groups, principally 
for persistent fever and with a similar range of antimicrobials. Moreover, in the majority 
of episodes in which initial treatment was modified, there was also a second modification. 
Subjective criteria were usually employed in both cases, suggesting that these decisions 
were made against a background of considerable uncertainty. A tendency to modify 
therapy according to subjective criteria was also noted in a recent study carried out by 
the EORTC International Antimicrobial Therapy Cooperative Group and the National 
Cancer Institute of Canada Clinical Trials Group (1991). This is a source of concern as 
it has been shown that, far from improving outcome, the liberal and inappropriate use 
of antibiotics actually increases both costs and the risks of superinfection (O'Hanley et aL,
1989).
As the assessment of outcome depends critically on how failure of therapy is defined, 
the criteria for modifying treatment should be specified beforehand; these criteria 
might also define persistent fever as lasting for at least 4 or 5 days (Donnelly et al., 1993), 
thereby acknowledging that a continuing fever does not necessarily mean that the original 
infection has not responded to treatment.
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It is interesting to note that the response rates in this study for episodes of fever of 
unknown origin were much higher than those for microbiologically and clinically defined 
infections, irrespective of whether or not an aetiology had been determined. Clearly, 
physicians are inclined to modify treatment more frequently when dealing with such 
infections, although prescribing additional antibacterials is likely to be futile as more 
infections which are only clinically defined, particularly those involving the lungs, are 
caused by fungi than by bacteria (Commers, Robichaud & Pizzo, 1984). A systemically 
active antifungal agent was, in fact, administered to almost one in five patients in each 
group and was the most popular choice for the first modification of therapy in patients 
who had failed to respond to meropenem, the assumption being that Gram-positive 
bacteria were adequately covered, at least initially, by this drug. On the other hand, in 
the ceftazidime group, there was a tendency to add either vancomycin or teicoplanin for 
bacteraemias caused by coaguiase-negative staphylococci, in the belief that the 
cephalosporin possessed less than optimal activity against these pathogens. The only 
means of overcoming this unwi tting bias would have been to blind the observers, but this 
was impossible at the time because of the characteristically unpleasant odour of 
ceftazidime. In reality, there appeared to be only minimal bias, as demonstrated by the 
observation that the indications for modification and the drugs used for this purpose were 
comparable in each group, suggesting that the responses of the clinicians would not have 
been significantly different had they been unaware of the empirical regimens to which the 
patients had been assigned.
Meropenem also fulfilled our expectations in terms of safety. Neither nausea nor 
seizures were observed, even in the six patients with histories of central nervous system 
disease. Hepatic and renal toxicities were rare and the incidence of skin rash was 
lower than that observed with ceftazidime. Meropenem also appears to be associated with 
fewer adverse events than imipenem/cilastatin (Winston et al., 1991; Leyland et a l, 1992), 
whereas the efficacies of the two drugs appear similar (Winston et al., 1991; Leyland et al, 
1992). It was also encouraging to note that all four episodes of infection caused by strains 
of E. cloacae responded to meropenem, particularly as relapses, resulting from 
derepression ofchromosomally-mediated p-lactamases, have been reported following the 
treatment of such infections with cephalosporins (Johnson & Ramphal, 1990).
In conclusion, meropenem has been shown in the present study to be both effective and 
well-tolerated treatment of febrile neutropenic patients and, given the high incidences of 
infections caused by coagulase-negative staphylococci and viridans streptococci, it 
appears to meet the current requirements of empirical antimicrobial therapy in this 
clinical setting.
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